Navigation Links
TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients
Date:1/10/2017

JACKSONVILLE, Fla., Jan. 10, 2017 /PRNewswire/-- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease today announced the opening of its Phase 2 company-sponsored ovarian cancer study in platinum-sensitive ovarian cancer patients. The company's first three clinical sites have received regulatory and Investigational Review Board (IRB) approval to begin enrollment. The study will utilize TPIV 200, a T-cell therapy targeting the folate receptor alpha protein.

This ovarian cancer study is an 80-patient double-blind placebo controlled study designed to examine the potential benefits of using the company's lead product candidate TPIV 200 in combination with standard of care chemotherapy. The study has Fast Track designation from the FDA and the product (TPIV 200) has orphan drug status for ovarian cancer.

Continue Reading
 (PRNewsFoto/TapImmune, Inc.)
(PRNewsFoto/TapImmune, Inc.)...

"The opening of this study represents the fulfillment of a major 2016 milestone," said Dr. John Bonfiglio, President and COO of TapImmune. "We now have three clinical studies utilizing TPIV 200 with approvals to enroll patients. A fourth study in triple-negative breast cancer sponsored by the Mayo clinic with a $13.3M grant from the Department of Defense is scheduled to begin shortly. We believe the depth of these clinical programs will give us an excellent understanding of how this exciting T-cell therapy can potentially be used in the treatment of both triple-negative breast and ovarian cancers."

About TapImmune, Inc.
TapImmune, Inc. is an immuno-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.

Please visit the company's website at www.tapimmune.com for more details. 

Forward-Looking Statement Disclaimer 
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-launches-phase-2-ovarian-cancer-trial-in-platinum-sensitive-patients-300388216.html


'/>"/>
SOURCE TapImmune, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. TapImmune: Year End 2016 Update
2. TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine
3. TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016
4. TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016
5. TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
6. TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine
7. TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
8. TapImmune to Present at Biotech Showcase 2016 in San Francisco on January 11, 2016
9. Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida
10. TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015
11. TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2019)... ... 14, 2019 , ... Life Molecular Imaging (LMI) and Chulabhorn ... a research collaboration to investigate the accumulation of beta-amyloid plaques and neurofibrillary Tau ... recruited and imaged. LMI and Chulabhorn Royal Academy leveraged their joint resources to ...
(Date:6/13/2019)... Colo. (PRWEB) , ... June 13, 2019 , ... ... thrilled to open its doors to a wellness center dedicated to realizing your ... of Atagi Plastic Surgery & Skin Aesthetics, BESANA Health & Wellness offers a ...
(Date:6/13/2019)... SHORE, N.Y. (PRWEB) , ... June 13, 2019 ... ... IP audio/video recording, IoT sensor technology and passive visual weapons detection systems, is ... Sensor and Milestone XProtect®. As a verified technology partner IPVideo’s award-winning ...
Breaking Medicine Technology:
(Date:6/18/2019)... PLEASANTON, Calif. (PRWEB) , ... June 18, 2019 ... ... (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced ... designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Aaron ...
(Date:6/16/2019)... ... 15, 2019 , ... All families go through tough times. When parents face ... lack of a support network, they may be unable to care for their children. ... home and place them with a relative, familiar caregiver or foster family while they ...
(Date:6/14/2019)... ... June 14, 2019 , ... ... Mattress & Pink Bag Event® scheduled for Saturday, July 13th. UBCF is thrilled ... and children directly impacted by breast cancer. This second event was added after ...
(Date:6/13/2019)... DETROIT (PRWEB) , ... June 13, 2019 , ... Endometriosis is a painful, inflammatory disease ... , Painful periods , Heavy bleeding , ... Constipation , Women’s Excellence uses the latest and newest treatment protocols in ...
(Date:6/13/2019)... ... June 13, 2019 , ... Charm Sciences, Inc. is pleased ... accepted by the 2019 National Conference of Interstate Milk Shipments for screening milk ... Charm BL30SEC test was validated by third party laboratories working in collaboration with ...
Breaking Medicine News(10 mins):